

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement appears for information purposes only and does not constitute any invitation or offer to acquire, purchase or subscribe for any securities.*



杭州啓明醫療器械股份有限公司

**Venus Medtech (Hangzhou) Inc.**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2500)**

**VOLUNTARY ANNOUNCEMENT**  
**EXPANDABLE BIOPROSTHETIC DRY TISSUE VALVE VENUS-NEO**  
**COMPLETED FIRST CLINICAL APPLICATION**

This announcement is made by Venus Medtech (Hangzhou) Inc. (the “**Company**”) on a voluntary basis. The board of directors of the Company (the “**Board**”) is pleased to announce that Venus-Neo, a new generation of expandable bioprosthetic dry tissue valve developed by the Company, has successfully completed the first clinical application of First-in-Man (FIM) trials in the Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

As the Company’s first surgical bioprosthetic valve, Venus-Neo features a supra-annular design with bovine pericardium tissue as the valve leaflet. With optimized valve design and unique anti-calcification dry tissue technology (Venus-Endura), Venus-Neo can be stored in a fluid-free environment without aldehyde residue, offering enhanced safety and facilitating clinical application, storage and transportation.

As China’s aging population increases, aortic valve disease has become one of the most common valvular heart diseases, and surgical aortic valve replacement (SAVR) is currently the standard treatment for the aortic stenosis and aortic regurgitation, with strong long-term clinical evidence. However, the high risk associated with reoperation after bioprosthetic valve deterioration cannot be ignored. Valve-in-valve procedure is increasingly being used in the treatment of surgical bioprosthetic valve deterioration, and Venus-Neo’s expansion zone provides a better choice for patients who may require the valve-in-valve treatment in the future.

This is another new generation of dry tissue valve product with special design from the Company that has entered clinical studies after Venus-Vitae and Venus-PowerX, marking a milestone for the Company to achieve a full layout of aortic valve disease solutions while enhancing the durability of bioprosthetic valves, consolidating the Company's position as a leader in the treatment of valvular heart diseases in China. The Board looks forward that the Company will complete Venus-Neo's clinical studies rapidly, by leveraging its technical advantage and continue its layout of new generation innovative products so as to benefit valvular heart disease patients worldwide.

By order of the Board  
**Venus Medtech (Hangzhou) Inc.**  
**Min Frank Zeng**  
*Chairman*

Hangzhou, April 12, 2022

*As at the date of this announcement, the executive Directors are Mr. Min Frank Zeng, Mr. Zhenjun Zi and Mr. Lim Hou-Sen (Lin Haosheng); the non-executive Director is Ms. Nisa Bernice Wing-Yu Leung; and the independent non-executive Directors are Mr. Ting Yuk Anthony Wu, Mr. Wan Yee Joseph Lau and Mr. Chi Wai Suen.*